Clin2
NCT05019885Possibly a fitRecruiting

IV ketamine for hard-to-treat epilepsy in adults

Drug Resistant EpilepsyMedically Refractory EpilepsyRefractory Epilepsy

Treatments studied

Part of Brain & nervous system clinical trials.

This Phase 2 study tests whether a low dose of IV ketamine can reduce seizures in adults with drug-resistant epilepsy. It may help people whose seizures continue despite trying at least two appropriate seizure medicines.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
8 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be an adult, age 18 or older
  • You’ve tried at least two appropriate seizure medicines and still have seizures
  • Your EEG test shows epilepsy that can be focal or generalized
  • In the past month, you must have more than 4 specific seizure types
  • Your seizure medicines (at least 1) must stay the same for about 12 weeks before starting
  • You must be able to safely participate (not pregnant, not breast feeding, not with certain heart/brain conditions)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07177235Not yet recruiting· Phase 4
Ketamine for hard-to-stop seizures

This trial tests if ketamine can help stop seizures that haven't responded to standard medicines. It is for adults whose seizures continue after two or more emergency treatments.

Philadelphia, Pennsylvania
NCT06788249Recruiting· Early Phase 1
Ketamine for treatment-resistant depression brain study

This trial tests whether a single dose of ketamine can quickly improve depression by studying brain chemical changes using MRI. It's for people with treatment-resistant depression who haven't used ketamine before.

Philadelphia, Pennsylvania
NCT07307768Not yet recruiting· Phase 1
Ketamine Biomarker Study for Severe Depression

This trial is for people with severe major depression who may benefit from a single dose of ketamine. Researchers want to see if certain biomarkers in your blood or brain can predict how well ketamine works for you.

New York, New York
NCT05915013Recruiting· Phase 1
Brain-targeting study of ketamine response in treatment-resistant depression

This early-stage study looks at how parts of brain cells respond to ketamine in people with depression who have not improved with usual antidepressants. It may help researchers find why ketamine works for some people and not others, and who might benefit.

New Haven, Connecticut
NCT06668571Recruiting· Phase 2
Ketamine for treatment-resistant depression

This study tests if intravenous ketamine can help people with treatment-resistant depression who haven't found relief from at least two other treatments. If you qualify, you'll receive ketamine infusions to see if it improves your mood.

Rochester, Minnesota
NCT07088380Recruiting· Phase 3
Ketamine combined with ECT for hard-to-treat depression

This trial tests whether adding ketamine to electroconvulsive therapy (ECT) works better than ECT alone for people with depression that hasn't improved with at least two different antidepressants. It may offer a new option for those who have not found relief from standard treatments.

Milan

Hear when a new Drug Resistant Epilepsy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.